319 related articles for article (PubMed ID: 21655990)
1. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
2. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
Hadad SM; Coates P; Jordan LB; Dowling RJ; Chang MC; Done SJ; Purdie CA; Goodwin PJ; Stambolic V; Moulder-Thompson S; Thompson AM
Breast Cancer Res Treat; 2015 Feb; 150(1):149-55. PubMed ID: 25682077
[TBL] [Abstract][Full Text] [Related]
3. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
[TBL] [Abstract][Full Text] [Related]
4. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
[TBL] [Abstract][Full Text] [Related]
5. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
7. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study.
Campagnoli C; Pasanisi P; Abbà C; Ambroggio S; Biglia N; Brucato T; Colombero R; Danese S; Donadio M; Venturelli E; Zito G; Berrino F
Clin Breast Cancer; 2012 Jun; 12(3):175-82. PubMed ID: 22607767
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
9. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
10. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
11. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer.
Joshua AM; Zannella VE; Downes MR; Bowes B; Hersey K; Koritzinsky M; Schwab M; Hofmann U; Evans A; van der Kwast T; Trachtenberg J; Finelli A; Fleshner N; Sweet J; Pollak M
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):252-8. PubMed ID: 24861559
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
Yee LD; Williams N; Wen P; Young DC; Lester J; Johnson MV; Farrar WB; Walker MJ; Povoski SP; Suster S; Eng C
Clin Cancer Res; 2007 Jan; 13(1):246-52. PubMed ID: 17200362
[TBL] [Abstract][Full Text] [Related]
13. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Goodwin PJ; Stambolic V
Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
[TBL] [Abstract][Full Text] [Related]
14. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
16. [Metformin does not suppress the aromatase expression in breast cancer tissue of patients with concurrent type 2 diabetes].
Bershteĭn LM; Turkevich EA; Boiarkina MP
Vopr Onkol; 2012; 58(2):194-8. PubMed ID: 22774523
[TBL] [Abstract][Full Text] [Related]
17. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ; Wierusz-Wysocka B
Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
[TBL] [Abstract][Full Text] [Related]
18. Targeting AMPK: a new therapeutic opportunity in breast cancer.
Hadad SM; Fleming S; Thompson AM
Crit Rev Oncol Hematol; 2008 Jul; 67(1):1-7. PubMed ID: 18343152
[TBL] [Abstract][Full Text] [Related]
19. The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial.
Refuerzo JS; Viteri OA; Hutchinson M; Pedroza C; Blackwell SC; Tyson JE; Ramin SM
Am J Obstet Gynecol; 2015 Mar; 212(3):389.e1-9. PubMed ID: 25526875
[TBL] [Abstract][Full Text] [Related]
20. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
